#9652 PTEN and PDK1 Antibody Sampler Kit
|Phospho-PTEN (Ser380/Thr382/383) (44A7) Rabbit mAb #9549||20 µl||WB||H, M, R, Mk||C||54||Rabbit IgG|
|PTEN (D4.3) XP® Rabbit mAb #9188||20 µl||WB, IP, IHC-P||H, M, R, Mk, Dg||C||54||Rabbit IgG|
|Phospho-PDK1 (Ser241) (C49H2) Rabbit mAb #3438||20 µl||WB, IP||H, M, R||58 to 68||Rabbit IgG|
|PDK1 Antibody #3062||20 µl||WB||H, M, R, Mk||C||58 to 68||Rabbit|
|Non-phospho PTEN (Ser380/Thr382/Thr383) (D2D11) Rabbit mAb #7960||20 µl||WB, IP||H, M, R, Mk||55||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||WB||Goat|
†Species predicted to react based on 100% sequence homology.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key: H=Human, M=Mouse, R=Rat, Mk=Monkey, Dg=Dog
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of extracts from SW-13, NIH/3T3, Jurkat and PC12 cells, using PDK1 Antibody.
Western blot analysis of extracts from HeLa and NIH/3T3 cells, using Phospho-PTEN (Ser380/Thr382/383) (44A7) Rabbit mAb. Membranes were either left untreated (-) or treated with (+) calf intestinal phosphatase (CIP) post Western transfer to verify phospho-specificity of the antibody.
Western blot analysis of extracts from various cell lines using PTEN (D4.3) XP® Rabbit mAb (upper) and Akt (pan) (C67E7) Rabbit mAb #4691 (lower).
Western blot analysis of extracts from PC3 cells, HCT116 wild-type and HCT116 PDK1 -/- cells using Phospho-PDK1 (Ser241) (C49H2) Rabbit mAb (upper) and Akt (pan) (C67E7) Rabbit mAb #4691 (lower). (HCT116 wild-type and HCT116 PDK1 -/- cells were kindly provided by Dr. Bert Vogelstein, Johns Hopkins University, Baltimore, MD).
Western blot analysis of extracts from various cell lines using Non-phospho PTEN (Ser380/Thr382/Thr383) (D2D11) Rabbit mAb. The non-phosphospecificity of the antibody was verified by preincubating the antibody without peptide (-), with PTEN (Ser380/Thr382/Thr383) non-phosphopeptide (+), or with PTEN (Ser380/Thr382/Thr383) phosphopeptide (+) prior to incubating the membrane.
Immunohistochemical analysis of paraffin-embedded human colon using PTEN (D4.3) XP® Rabbit mAb.
Western blot analysis of extracts from PC3 cells, untreated or λ phosphatase-treated, using Phospho-PDK1 (Ser241) (C49H2) Rabbit mAb (upper), PDK1 Antibody #3062 (middle) or Akt Antibody #9272 (lower).
Immunohistochemical analysis using PTEN (D4.3) XP® Rabbit mAb on SignalSlide(TM) PTEN IHC Controls #8106 (paraffin-embedded LNCaP (left) and NIH/3T3 (right) cells).
PTEN (phosphatase and tensin homologue deleted on chromosome ten), also referred to as MMAC (mutated in multiple advanced cancers) phosphatase, is a tumor suppressor implicated in a wide variety of human cancers (1). PTEN encodes a 403 amino acid polypeptide originally described as a dual-specificity protein phosphatase (2). The main substrates of PTEN are inositol phospholipids generated by the activation of the phosphoinositide 3-kinase (PI3K) (3). PTEN is a major negative regulator of the PI3K/Akt signaling pathway (1,4,5). PTEN possesses a carboxy-terminal, noncatalytic regulatory domain with three phosphorylation sites (Ser380, Thr382, and Thr383) that regulate PTEN stability and may affect its biological activity (6,7). PTEN regulates p53 protein levels and activity (8) and is involved in G protein-coupled signaling during chemotaxis (9,10).
Phosphoinositide-dependent protein kinase 1 (PDK1) plays a central role in many signal transduction pathways (11,12) including the activation of Akt and the PKC isoenzymes p70 S6 kinase and RSK (13). Through its effects on these kinases, PDK1 is involved in the regulation of a wide variety of processes, including cell proliferation, differentiation and apoptosis.
- Cantley, L.C. and Neel, B.G. (1999) Proc Natl Acad Sci USA 96, 4240-5.
- Myers, M.P. et al. (1997) Proc Natl Acad Sci USA 94, 9052-7.
- Myers, M.P. et al. (1998) Proc Natl Acad Sci USA 95, 13513-8.
- Wan, X. and Helman, L.J. (2003) Oncogene 22, 8205-11.
- Wu, X. et al. (1998) Proc Natl Acad Sci USA 95, 15587-91.
- Vazquez, F. et al. (2000) Mol Cell Biol 20, 5010-8.
- Torres, J. and Pulido, R. (2001) J Biol Chem 276, 993-8.
- Freeman, D.J. et al. (2003) Cancer Cell 3, 117-30.
- Funamoto, S. et al. (2002) Cell 109, 611-23.
- Iijima, M. and Devreotes, P. (2002) Cell 109, 599-610.
- Belham, C. et al. (1999) Curr Biol 9, R93-6.
- Toker, A. and Newton, A.C. (2000) Cell 103, 185-8.
- Williams, M.R. et al. (2000) Curr Biol 10, 439-48.
XP is a registered trademark of Cell Signaling Technology, Inc.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.